COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 3 for:    SNG001
Previous Study | Return to List | Next Study

Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04385095
Recruitment Status : Recruiting
First Posted : May 12, 2020
Last Update Posted : May 12, 2020
Information provided by (Responsible Party):
Synairgen Research Ltd.

Brief Summary:

SNG001 is an inhaled drug that contains a antiviral protein called interferon beta (IFN-β). IFN-β in produced in the lungs during viral lung infections. It has been shown that older people and people with some chronic diseases have an IFN-β deficiency. Many viruses inhibit IFN-β as part of their strategy to evade the immune system.

Addition of IFN-β in vitro protects lung cells from viral infection. IFN-β protects cells against the MERS and SARS coronaviruses (close relatives of SARS-CoV-2, the virus that causes COVID-19).

SNG001 is an inhaled formulation of interferon beta-1a it is currently in Phase II clinical trials for COPD patients.

Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. These trials have shown that SNG001 has:

  • been well tolerated during virus infections
  • enhanced antiviral activity in the lungs (measured in sputum and blood samples)
  • provided significant lung function benefit over placebo in asthma in two Phase II trials.

Synairgen believes SNG001 could help prevent worsening or accelerate recovery of severe lower respiratory tract illness in COVID-19 patients.

Patients who are in hospital or non-hospitalised but are a high risk groups (e.g. elderly or diabetics) will be invited to take part in the trial. The patient would receive either SNG001 or placebo once daily for 14 days. The severity of the patients condition would be recorded on a scale developed by the World Health Organisation and the patient would be asked questions about their breathlessness, cough and sputum every day, as well as assess their general medical condition and safety.

If SNG001 proves to be beneficial it would be a major breakthrough for the treatment of COVID-19.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Drug: Interferon beta 1a Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomised double-blind placebo-controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection
Actual Study Start Date : March 16, 2020
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : May 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: SNG001
inhalation using the I-neb device.
Drug: Interferon beta 1a
Interferon Beta-1A via inhalation
Other Name: SNG001

Placebo Comparator: Placebo
inhalation using the I-neb device.
Drug: Placebo
Placebo via inhalation

Primary Outcome Measures :
  1. Ordinal Scale for Clinical Improvement [ Time Frame: Day 1 to day 28 ]
    Change in condition measured using the Ordinal Scale for Clinical Improvement during the dosing period - minimum of 0 (patient is well) to a maximum of 8 (death)

Secondary Outcome Measures :
  1. Progression to pneumonia [ Time Frame: Day 2 to day 28 ]
    Progression to pneumonia as diagnosed by chest x-ray, if no pneumonia is present at time of enrolment

  2. Progression to pneumonia [ Time Frame: Day 1 to day 28 ]
    Evolution of pneumonia, as diagnosed by chest x-ray, if pneumonia is present at time of enrolment

  3. Time to clinical improvement [ Time Frame: Time to hospital discharge OR Time to NEWS2 of ≤ 2 maintained for 24 hours ]
    Time to clinical improvement

  4. National Early Warning Score 2 (NEWS2) assessment of acute-illness severity [ Time Frame: Day 1 to day 28 ]
    NEWS2 assessment of acute-illness severity on a scale of 0 ( being well) up to 24 (requiring emergency response)

  5. Changes in daily breathlessness, cough and sputum scale (BCSS) [ Time Frame: Day 1 to day 28 ]
    Changes in daily breathlessness, cough and sputum scale (BCSS) on a scale of 0 (no symptoms) up to 4 (severe symptoms)

  6. Safety and tolerability - blood pressure II. Viral load [ Time Frame: Day 1 to day 28 ]
    Looking at blood pressure measured in mmHg

  7. Safety and tolerability - heart rate II. Viral load [ Time Frame: Day 1 to day 28 ]
    Looking at heart rate measured in beats per minute

  8. Safety and tolerability - temperature II. Viral load [ Time Frame: Day 1 to day 28 ]
    Looking at temperature measured in degrees Celsius

  9. Safety and tolerability - respiratory rate II. Viral load [ Time Frame: Day 1 to day 28 ]
    Looking at respiratory rate measure in breaths per minute

  10. Safety and tolerability - oxygen saturation II. Viral load [ Time Frame: Day 1 to day 28 ]
    Looking at oxygen levels measured in a %

  11. Safety and tolerability - adverse events II. Viral load [ Time Frame: Day 1 to day 28 ]
    Looking at adverse events (numbers and terms)

  12. Safety and tolerability - concomitant medications II. Viral load [ Time Frame: Day 1 to day 28 ]
    Looking at concomitant medications given during treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Positive virus test for SARS-CoV-2 using RT-PCR or positive point-of-care viral infection test in the presence of strong clinical suspicion of SARS-CoV-2 infection
  2. Male or female, ≥18 years of age at the time of consent
  3. Patients admitted to hospital due to the severity of their confirmed or suspected COVID-19 disease OR non-hospitalised patients from high-risk co-morbidity groups such as the >65-years of age, or those with hypertension, cardiovascular disease, diabetes, a chronic lung condition, cancer, or frontline healthcare workers. (The Sponsor will inform sites as to whether non-hospitalised patients are to be entered into the trial).
  4. Provide informed consent.
  5. Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception.

Exclusion Criteria:

  1. > 24 hours after confirmation of SARS-CoV-2 infection by RT-PCR test
  2. Any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation.
  3. Current or previous participation in another clinical trial where the patient has received a dose of an IMP containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.
  4. Ventilated or in intensive care
  5. Inability to use a nebuliser with a mouthpiece.
  6. History of hypersensitivity to natural or recombinant IFN-β or to any of the excipients in the drug preparation.
  7. Patients that are taking an antiviral treatment (e.g. zanamivir or oseltamivir) prior to randomisation and/or on the day of randomisation
  8. Female who are breast-feeding, lactating, pregnant or intending to become pregnant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04385095

Layout table for location contacts
Contact: Jody Brookes 02380512800
Contact: Sophie Hemmings 02380512800

Layout table for location information
United Kingdom
Belfast City Hospital Not yet recruiting
Belfast, United Kingdom, BT9 7AB
Contact: Lorcan McGarvey, MD FRCP         
Queen Elizabeth Hospital, Recruiting
Birmingham, United Kingdom, B15 2GW
Contact: Davinder Dosanjh, DPhil, MRCP, FHEA         
Bradford Royal Infirmary Recruiting
Bradford, United Kingdom, BD9 6RJ
Contact: Dinesh Saralaya, MBBS MD MRCP FRCP         
Hull and East Yorkshire NHS Trust, Castle Hill Hospital, Recruiting
Hull, United Kingdom, HU16 5JQ
Contact: Michael Crooks, MBBS         
Glenfield Hospital, Recruiting
Leicester, United Kingdom, LE3 9QP
Contact: Salman Siddiqui, Fellow of the Royal College of         
Wythenshawe Hospital Recruiting
Manchester, United Kingdom, M23 9LT
Contact: Jaclyn Smith, MB ChB MRCP PhD FRCP         
City Campus of Nottingham University Recruiting
Nottingham, United Kingdom, NG5 1PB
Contact: Tim Harrison, MBBS FRCP MD         
John Radcliffe Hospital Recruiting
Oxford, United Kingdom, OX3 9DU
Contact: Najib Rahman, MB BCh MA         
University Hospital Southampton Nhs Foundation Trust Recruiting
Southampton, United Kingdom, SO16 6YD
Contact: Tom Wilkinson   
Principal Investigator: Tom Wilkinson         
Sponsors and Collaborators
Synairgen Research Ltd.
Layout table for investigator information
Principal Investigator: Tom Wilkinson Study Principal Investigator
Layout table for additonal information
Responsible Party: Synairgen Research Ltd. Identifier: NCT04385095    
Other Study ID Numbers: SG016
First Posted: May 12, 2020    Key Record Dates
Last Update Posted: May 12, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No plan to share data

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Synairgen Research Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Interferon beta-1a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic